文献库搜索 | GeneLibs

Campani(C),Laurent-Puig(P),Villeret(F),Ben... J Hepatol 2026-08-00

...PIK3CA (22%), and ARID2 (11%) in cHCC-CCA. Among 103 interpretable genomes, 67 patients harbored at least one actionable...

Huang(J),Wang(Z),Liu(J),Zhang(J),Deng(K),H... Drug Des Devel Ther None

...PIK3CA as a pivotal target, substantiated by molecular docking studies (binding energy of -8.0 kcal/mol) and rescue expe...

Zhang(C),Deng(R),Zhang(W),Liu(Z),Chen(F),W... BMC Cancer 2026-03-23

...PIK3CA (6.3% each). For first-line EGFR-TKIs, the overall objective response rate (ORR) reached 68.8%, with a median pro...

Abdel-Razeq(H),Sharaf(B) Curr Oncol 2026-07-14

...PIK3CA-mutated tumors who had progressed on or within 12 months of completing adjuvant ET and had no prior systemic ther...

Qi(H),Wen(J),Xu(H) Expert Opin Ther Pat 2026-07-30

...PIK3CA mutations drive numerous solid tumors, rendering PI3Kα a key therapeutic target. However, conventional ATP-compet...

Oliveira(CE),Júnior(JACN),Santos(CR),Barre... Recent Pat Anticancer Drug ... 2026-07-21

...PIK3CA inhibitors, which are effective in patients with specific mutations in this gene, which are commonly found in HR+...

Voutsadakis(IA) Genes (Basel) 2026-06-30

...PIK3CA, and the epigenetic modifiers ARID1A and BCOR were common. PIK3CA mutations were observed in 80% of EBV-associate...

Chen(L),Severino(E),Wu(DS),Singh(B),Segars... Biomedicines 2026-07-20

...PIK3CA, CTNNB1, CHD4, MYD88, and STAG2. Conclusions: This study detected mutations in KRAS, ARID1A, PIK3CA, CTNNB1, and ...

Unuofin(JO),Adefisan-Adeoye(AO),Paimo(OK),... Molecules 2026-07-22

...PIK3CA), and TP53, in driving tumor initiation, progression, and therapeutic response. Molecular profiling and next-gene...

Tomic(U),Petrovic(S),Mihailovic(D),Carkic(... Microorganisms 2026-07-14

...PIK3CA, DUSP16, mTOR, and MAPK14 was analyzed by RT-qPCR. C. gingivalis was detected in 2 benign lesions, 11 OPMDs, and ...